يعرض 1 - 10 نتائج من 17 نتيجة بحث عن '"Rama Krishna Narla"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
    دورية أكاديمية
    SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma

    المؤلفون: Alexander C. Leeksma, Ingrid A. M. Derks, Brett Garrick, Aldo Jongejan, Martino Colombo, Timon Bloedjes, Torsten Trowe, Jim C. Leisten, Michelle Howarth, Mehnaz Malek, Deborah S. Mortensen, Kate Blease, Mathew C. Groza, Rama Krishna Narla, Remco Loos, Marie‐José Kersten, Perry D. Moerland, Jeroen E. J. Guikema, Arnon P. Kater, Eric Eldering, Ellen H. Filvaroff

    المصدر: Molecular Oncology, Vol 17, Iss 2, Pp 284-297 (2023)

    مصطلحات موضوعية: cancer, MM, NMD, SMG1, therapy, UPR, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261

    URL الوصول: https://doaj.org/article/702d5efc32b54942a82e101ab9e8166c

    View record at Wiley Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma

    المؤلفون: Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

    المصدر: mAbs, Vol 16, Iss 1 (2024)

    مصطلحات موضوعية: CD20, CD47, detune, non-Hodgkin’s lymphoma, phagocytosis, Therapeutics. Pharmacology, RM1-950, Immunologic diseases. Allergy, RC581-607

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1942-0862; https://doaj.org/toc/1942-0870

    URL الوصول: https://doaj.org/article/2baf8cb3663d44fba094537b05a4fc5d

    PDF full text from Publisher Full Text Finder
    أضف إلى المفضلة
  3. 3
    SMG1 , a nonsense‐mediated mRNA decay ( NMD ) regulator, as a candidate therapeutic target in multiple myeloma

    المؤلفون: Alexander C. Leeksma, Ingrid A. M. Derks, Brett Garrick, Aldo Jongejan, Martino Colombo, Timon Bloedjes, Torsten Trowe, Jim C. Leisten, Michelle Howarth, Mehnaz Malek, Deborah S. Mortensen, Kate Blease, Mathew C. Groza, Rama Krishna Narla, Remco Loos, Marie‐José Kersten, Perry D. Moerland, Jeroen E. J. Guikema, Arnon P. Kater, Eric Eldering, Ellen H. Filvaroff

    المساهمون: Hematology, Graduate School, Experimental Immunology, CCA - Cancer biology and immunology, Epidemiology and Data Science, APH - Methodology, Pathology, CCA - Imaging and biomarkers, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, APH - Personalized Medicine, AII - Infectious diseases, AII - Cancer immunology

    المصدر: Molecular oncology. Elsevier
    Leeksma, A C, Derks, I A M, Garrick, B, Jongejan, A, Colombo, M, Bloedjes, T, Trowe, T, Leisten, J C, Howarth, M, Malek, M, Mortensen, D S, Blease, K, Groza, M C, Narla, R K, Loos, R, Kersten, M-J, Moerland, P D, Guikema, J E J, Kater, A P, Eldering, E & Filvaroff, E H 2022, ' SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma ', Molecular oncology . https://doi.org/10.1002/1878-0261.13343

    مصطلحات موضوعية: therapy, Cancer Research, Oncology, SMG1, Genetics, NMD, cancer, Molecular Medicine, UPR, General Medicine, MM

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc34b2dab0571f6f622996e577edf883
    https://doi.org/10.1002/1878-0261.13343

    View record at Wiley Find this article in full text from ProQuest
    أضف إلى المفضلة
  4. 4
    Structure-based optimization of aminothiadiazole inhibitors of AKT

    المؤلفون: Deborah S. Mortensen, Sayee G. Hegde, Sophie M. Perrin-Ninkovic, Sogole Bahmanyar, Meg McCarrick, Roy Harris, Robert Hilgraf, Branden G. S. Lee, Jeff McKie, Lisa Nadolny, John Sapienza, Alice Collette, Sarah Cox, James C. Gamez, Jennifer L. Hensel, Xuequn Helen Hua, Jim Leisten, Heather K. Raymon, Tam Tran, Rama Krishna Narla

    المصدر: Medicinal Chemistry Research.

    مصطلحات موضوعية: Organic Chemistry, General Pharmacology, Toxicology and Pharmaceutics

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::612328f1499c3dbf3b9a40a6048d43ce
    https://doi.org/10.1007/s00044-023-03072-4

    Find this article in full text from Springer Verlag.
    أضف إلى المفضلة
  5. 5
    Data from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

    المؤلفون: John F. Boylan, Jennifer R. Riggs, Heather K. Raymon, Ning Jiang, Tao Shi, Yuhong Ning, David Mikolon, Tam Tran, Rama Krishna Narla, Leo A. Barnes, Sophie X. Peng, Gordafaried Deyanat-Yazdi, Shuichan Xu, Dan Zhu

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc39d765a5b86cd0bea57f9dd0bcd25
    https://doi.org/10.1158/1535-7163.c.6537733

    أضف إلى المفضلة
  6. 6
    Supplementary Figures S1-S3, Tables S1-S7 from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

    المؤلفون: Heather K. Raymon, Sabita Sankar, Peter Worland, Stacie S. Canan, Mehran F. Moghaddam, Brian E. Cathers, Zeen Tong, Wen Qing Yang, Tao Shi, Tam Tran, Sophie Perrin-Ninkovic, Sophie X. Peng, Samantha Richardson, Rene Bissonette, Rama Krishna Narla, Matt Hickman, Kamran Ghoreishi, Julius Apuy, Jingjing Zhao, Jim Leisten, James C. Gamez, Godrej Khambatta, Garrick Packard, Weiming Xu, Shuichan Xu, Kimberly E. Fultz, Deborah S. Mortensen

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106516d185208367e68bb96ffc0bed07
    https://doi.org/10.1158/1535-7163.22500843.v1

    أضف إلى المفضلة
  7. 7
    Supplemental Methods; Supplemental Tables S1-S7; and Supplemental Figures S1-S6 from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

    المؤلفون: John F. Boylan, Jennifer R. Riggs, Heather K. Raymon, Ning Jiang, Tao Shi, Yuhong Ning, David Mikolon, Tam Tran, Rama Krishna Narla, Leo A. Barnes, Sophie X. Peng, Gordafaried Deyanat-Yazdi, Shuichan Xu, Dan Zhu

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345d2d16f0cdc9dbe61ef20d892594b3
    https://doi.org/10.1158/1535-7163.22504438.v1

    أضف إلى المفضلة
  8. 8
    Data from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

    المؤلفون: Heather K. Raymon, Sabita Sankar, Peter Worland, Stacie S. Canan, Mehran F. Moghaddam, Brian E. Cathers, Zeen Tong, Wen Qing Yang, Tao Shi, Tam Tran, Sophie Perrin-Ninkovic, Sophie X. Peng, Samantha Richardson, Rene Bissonette, Rama Krishna Narla, Matt Hickman, Kamran Ghoreishi, Julius Apuy, Jingjing Zhao, Jim Leisten, James C. Gamez, Godrej Khambatta, Garrick Packard, Weiming Xu, Shuichan Xu, Kimberly E. Fultz, Deborah S. Mortensen

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4ce3c68a5bf01dbc4b5578e36679e558
    https://doi.org/10.1158/1535-7163.c.6536589.v1

    أضف إلى المفضلة
  9. 9
    Author response for 'SMG1 , a nonsense‐mediated mRNA decay ( NMD ) regulator, as a candidate therapeutic target in multiple myeloma'

    المؤلفون: null Alexander C. Leeksma, null Ingrid A.M. Derks, null Brett Garrick, null Aldo Jongejan, null Martino Colombo, null Timon Bloedjes, null Torsten Trowe, null Jim C. Leisten, null Michelle Howarth, null Mehnaz Malek, null Deborah S. Mortensen, null Kate Blease, null Mathew C. Groza, null Rama Krishna Narla, null Remco Loos, null Marie‐José Kersten, null Perry D. Moerland, null Jeroen E.J. Guikema, null Arnon P. Kater, null Eric Eldering, null Ellen H. Filvaroff

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d9b140e3e634f7c3b24cd9a9e52bc733
    https://doi.org/10.1002/1878-0261.13343/v2/response1

    أضف إلى المفضلة
  10. 10
    Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)

    المؤلفون: Soraya Carrancio, Celia Fontanillo, Ryan Galasso, Martino Colombo, Scott Wood, Carla Guarinos, Alejandro Panjkovich, Diana Jankeel, Adam Blattler, Preethi Janardhanan, Matthew Groza, Jim Leisten, Rama Krishna Narla, Antonia Lopez-Girona, Daniel W. Pierce

    المصدر: Cancer Research. 82:3932-3932

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::aae89c5f86e6513ab832ad6937285212
    https://doi.org/10.1158/1538-7445.am2022-3932

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء